Company Overview: Renalytix PLC (LON: RENX) is a United Kingdom-based company, which is engaged in the development of artificial intelligence-enabled clinical diagnostic solutions for kidney disease. The Company is engaged in a field of bio prognosis for kidney health. This Report covers the Price Action, Technical Indicators Analysis along with the Support Levels, Resistance Levels, and Recommendations on this stock.
Fundamental Highlights:
Strategic Review in Progress Amid Slower Sales - The company has acknowledged that Eroxon’s market uptake has been slower than initially expected, with variable performance across different regions. In response, a comprehensive review of commercial strategy and cost structure is underway, with an update expected alongside interim results later this month. Futura Medical has confirmed the formal appointment of Alex Duggan as interim CEO, bringing significant sector experience at a time when the company is reassessing its commercial direction. The planned departure of Finance Director and COO Angela Hildreth signals further executive change as the Group navigates this transitional phase.
Q3 2025 Trading Update
Renalytix PLC delivered Q3 performance in line with expectations, supported by a 20% sequential increase in revenues and a notable milestone of surpassing 1,000 billable tests in a single quarter. The integration of a large New York-based primary care network appears to be contributing meaningfully to testing volume growth. From an external perspective, the company's ability to generate reimbursement from Medicare and commercial insurers is a constructive sign for broader clinical adoption. However, the overall revenue base remains modest, and sustained scalability will likely be key for investor confidence moving forward.
RENX’s Technical Observation:
RENX closed at GBX 7.30, down 5.81%, after retreating from recent highs. The stock tested a rising low but continues to hold its key support at GBX 6.39, reflecting resilience and maintaining a stable structure. The RSI at 59.40 remains in bullish territory and is showing signs of stabilising, indicating room for recovery if momentum improves. In the near term, sustaining above GBX 6.39 and GBX 5.11 will be crucial for preserving a constructive outlook. On the upside, resistance levels are located at GBX 8.21 and GBX 9.49, which will serve as important markers for any potential advance.


RENX’s Daily Chart

RENX Daily Technical Chart, Source – Refinitiv

As per the above-mentioned price action and technical indicators analysis, a ‘Speculative Buy’ rating has been given on Renalytix PLC (LON: RENX) at the Closing Market Price of GBX 7.30, as of September 17, 2025. Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario.
Markets are trading in a highly volatile zone currently due to certain Macro & Micro-economic data and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.
Note 1: Past performance is not a reliable indicator of future performance.
Note 2: Investment decisions should be made depending on an individual’s appetite for upside potential, risks, and any previous holdings. This recommendation is purely based on technical analysis, and fundamental analysis has not been considered in this report. Individuals can consider exiting from the stock if the Target Price or Stop loss mentioned as per the technical analysis has been achieved and is subject to the factors discussed above.
Note 3: Related Risks: This report may be looked at from a high-risk perspective and recommendations are provided for a short duration. Recommendations provided in this report are solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rate risks, currency risks, social and political instability risks etc.
Note 4: How to Read the Charts
The Green colour line reflects the 21-period moving average while the red line indicates the 50- period moving average. SMA helps to identify existing price trends. If the prices are trading above the 21-period and 50-period moving average, then it shows prices are currently trading in a bullish trend.
The Black colour line in the chart’s lower segment reflects the Relative Strength Index (14-Period) which indicates price momentum and signals momentum in trend. A reading of 70 or above suggests overbought status while a reading of 30 or below suggests an oversold status.
The Blue colour bars in the chart’s lower segment show the volume of the stock. The volume is the number of shares that changed hands during a given day. Stocks with high volumes are more liquid than stocks with lesser volume as liquidity in stocks helps in easier and faster execution of the order.
The Orange colour lines are the trend lines drawn by connecting two or more price points and used for trend identification purposes. The trend line also acts as a line of support and resistance.
Technical Indicators Defined: -
Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.
Resistance: A level at which stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Resistance 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Resistance 2 may act as the crucial resistance level for the stock.
Stop-loss: It is a level to protect against further losses in case of unfavorable movement in the stock prices.
The reference date for all price data, currency, technical indicators, support, and resistance levels is September 17, 2025. The reference data in this report has been partly sourced from REFINITIV.
Abbreviations
CMP: Current Market Price
SMA: Simple Moving Average
GBP: British pound sterling
GBX: British pence sterling
RSI: Relative Strength Index
USD: United States dollar
Note: Trading decisions require a thorough analysis by individuals. Technical reports in general chart out metrics that may be assessed by individuals before any stock evaluation. The above are illustrative analytical factors used for evaluating stocks; other parameters can be looked at along with additional risks per se. Past performance is neither an indicator nor a guarantee of future performance.
This report has been issued by Kalkine Limited (Company number 07903332), a private limited company, incorporated in England and Wales ("Kalkine”). Kalkine.co.uk and associated pages are published by Kalkine. Kalkine is authorised and regulated by the Financial Conduct Authority under reference number 579414.
The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice. The information in this report does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products. Our reports contain non personalized recommendations to invest in securities and other financial products.
Kalkine does not offer financial advice based upon your personal financial situation or goals, and we shall not be held liable for any investment or trading losses you may incur by using the opinions expressed in our reports, publications, market updates, news alerts and corporate profiles. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation. Kalkine’s non-personalised advice does not in any way endorse or recommend individuals, investment products or services for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional authorised financial planner and adviser. You should be aware that the value of any investment and the income from it can go down as well as up and you may not get back the amount invested.
Please also read our Terms & Conditions for further information. Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this report or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.
Kalkine Media Limited, an affiliate of Kalkine, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website including entities covered in this report.
Past performance is not a reliable indicator of future performance.